Silvia Mappa - Concepedia

Author

Silvia Mappa

Istituti di Ricovero e Cura a Carattere Scientifico

Also Known As

Mappa S., S Mappa, S. Mappa, Silvia Mappa

Publications

683

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico University of Florence Azienda Ospedaliera Citta' della Salute e della Scienza di Torino Azienda Ospedaliero-Universitaria Careggi Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

About

Silvia Mappa is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	147
2	Immunology	2	2	88
3	Pathology	2	2	27
4	Health Sciences	1	1	12
5	Orthopaedics	1	1	15

Silvia Mappa

Publications

570

Citations

H-Index

Page 1

	Year	Citations
<i>Chlamydophila Psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial Andrés J.M. Ferreri, Silvia Govi, Elisa Pasini, Journal of Clinical Oncology	2012	167
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R‐IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high‐dose methotrexate‐based chemotherapy Silvia Mappa, Emerenziana Marturano, Giada Licata, Hematological Oncology Stem Cell CollectionLymphoid NeoplasiaMedicineRefractory PcnslImmunology	2012	76
Prevalence of <i>Borrelia Burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas Maurilio Ponzoni, Andrés J.M. Ferreri, Silvia Mappa, The Oncologist	2011	66
Liposome‐encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre‐treated with anthracyclines Luigi Rigacci, Silvia Mappa, Luca Nassi, Hematological Oncology	2007	63
Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas Luigi Rigacci, Luca Nassi, Marco Puccioni, Annals of Hematology Lymphoid NeoplasiaOcular DiseaseOphthalmologyFirst-line TreatmentGlaucoma	2007	44
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents Andrew D.J. Pearson, C. Michel Zwaan, E. Anders Kolb, European Journal of Cancer	2020	43
Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma Martin Dreyling, Franck Morschhauser, Dominique Bron, Blood	2013	35
Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma Martin Dreyling, David Cunningham, Krimo Bouabdallah, Blood	2014	17
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy Fevzi Yalniz, Jesús G. Berdeja, Michael B. Maris, British Journal of Haematology	2019	16
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum Andrés J.M. Ferreri, Marianna Sassone, Elisabetta Miserocchi, Blood Advances	2020	16

Page 1